AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacturing, and commercialization of prescription medicines. Its marketed products include Calquence, Enhertu, Faslodex, Imfinzi, Iressa, Koselugo, Lumoxiti, Lynparza, Orpathys, Tagrisso, and Zoladex for oncology; Brilinta/Brilique, Bydureon/Byetta, BCise, Byetta, Crestor, Evrenzo, Farxiga/Forxiga, Komboglyze/Kombiglyze XR, Lokelma, Onglyza, Qtern, and Xigduo/Xigduo XR for cardiovascular, renal, and metabolism diseases; Bevespi Aerosphere, Breztri Aerosphere, Daliresp/Daxas, Duaklir Genuair, Fasenra, Pulmicort, Saphnelo, Symbicort, and Tudorza/Eklira/Bretaris for respiratory and immunology; and Andexxa/Ondexxya, Kanuma, Soliris, Strensiq, and Ultomiris for rare diseases. The company's marketed products also comprise Synagis for respiratory syncytial virus; Fluenz Tetra/FluMist Quadrivalent for Influenza; Seroquel IR/Seroquel XR for schizophrenia bipolar disease; Nexium, and Losec/Prilosec for gastroenterology; and Vaxzevria and Evusheld for covid-19. The company serves primary care and specialty care physicians through distributors and local representative offices in the United Kingdom, rest of Europe, the Americas, Asia, Africa, and Australasia. It has a collaboration agreement with Regeneron Pharmaceuticals, Inc. to research, develop, and commercialize small molecule medicines for obesity; Neurimmune AG to develop and commercialize NI006; Ionis Pharmaceuticals, Inc. to develop eplontersen, a liver-targeted antisense therapy in Phase III development for the treatment of transthyretin amyloidosis; Proteros Biostructures GmbH to jointly discover novel small molecules for the treatment of hematological cancers; Sierra Oncology, Inc. to develop and commercialize AZD5153. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.

AstraZeneca PLC

Derivative Acquisition Under Employee Benefit Plan

Insider	Title	Transaction Type	Shares Traded	% of Shares Traded	% Chg. in Shares	End of Filing Shares	Price	Transaction Value	Filing Date	Transaction Date
Pascal Soriot	CEO & Executive Director, Chief Executive Officer of Astrazeneca Plc Show All	Other Disposition (Sale)	-297.42K	-0.019185%	-59.63%	201.36K	—	—	12 Jun 2024	10 Jun 2024 - 10 Jun 2024
Pascal Soriot	CEO & Executive Director, Chief Executive Officer of Astrazeneca Plc Show All	Derivative Acquisition Under Employee Benefit Plan (Buy)	29.47K	—	—	—	—	—	15 May 2024	13 May 2024 - 13 May 2024
Pascal Soriot	CEO & Executive Director, Chief Executive Officer of Astrazeneca Plc Show All	Derivative Exercise and Retained Stock (Buy)	105.24K	0.006788%	26.74%	498.77K	—	—	12 Mar 2024	08 Mar 2024 - 08 Mar 2024
Pascal Soriot	CEO & Executive Director, Chief Executive Officer of Astrazeneca Plc Show All	Derivative Exercise and Retained Stock (Buy)	17.7K	0.001141%	4.71%	393.54K	—	—	06 Mar 2024	05 Mar 2024 - 05 Mar 2024
Pascal Soriot	CEO & Executive Director, Chief Executive Officer of Astrazeneca Plc Show All	Derivative Acquisition Under Employee Benefit Plan (Buy)	109.87K	—	—	—	—	—	06 Mar 2024	04 Mar 2024 - 04 Mar 2024
Aradhana Sarin
Pascal Soriot
Michel Demare
Michel Demare
Pascal Soriot
Pascal Soriot
Aradhana Sarin
Pascal Soriot
Pascal Soriot
Aradhana Sarin
Aradhana Sarin
Pascal Soriot
Aradhana Sarin
Pascal Soriot
Pascal Soriot
Aradhana Sarin